If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
ARYA Sciences Acquisition III (ARYA)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

ADC Therapeutics SA (ADCT)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a late clinical-stage oncology-focused biotechnology company evolving into a commercial-stage company as they prepare for the launch of their lead product candidate, if approved. They are a pioneer in the development of highly potent and targeted antibody drug conjugates (“ADCs”) for patients suffering from hematological malignancies and solid tumors. They develop their ADCs by applying their decades of experience in this field and using next-generation pyrrolobenzodiazepine (“PBD”) technology to which they have proprietary rights for their targets. They are leveraging their R&D strengths, their disciplined approach to target selection and their preclinical and clinical development strategy to generate a diverse and balanced portfolio and research pipeline. Their hematology franchise comprises three clinical-stage product candidates, loncastuximab tesirine (“Lonca” and previously known as ADCT-402), camidanlumab tesirine (“Cami” and previously known as ADCT-301) and ADCT-602. Their solid tumor franchise comprises two clinical-stage product candidates, Cami and ADCT-601, and two preclinical product candidates, ADCT-901 and ADCT-701.
Christopher Martin Michael Forer
Employees Founded
138 2011


Address: Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland

Telephone: +41 21 653 02 00

Web page:

IPO information

Expected Date 5/15/2020
Status Priced
Exchange NYSE
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $23.00-$26.00
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $1136.8
Revenues (MM) $2.34
Net Income (Loss) (MM) $-116.5


What do you think will happen with the ADCT share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 8.2
Shares Revised (MM) 12.3
Expected offer amount (MM) $175
Realized offer amount(MM) $233.7
Morgan Stanley/ BofA Merrill Lynch/ Cowen

Sector: Healthcare

Tweets about $ADCT

Tweets volume:

RT volume:


Google Trends Stats